1 of 3
The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world, including nine blockbuster drugs, and nowadays represent the mainstay products of the biotechnology industry.
This book is unique in introducing readers to a comprehensive set of recently developed technologies, showing paradigm shifts in the health care system and reflecting these changes in industrial research.
Here, the world′s top scientists and business leaders divulge their first–hand expertise, allowing you to participate in their recent achievements. They all have their own specific contribution and have been carefully selected to provide a multifaceted and unique insight. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel laureates Robert Huber and Thomas R. Cech, as well as authors from the world′s most famous academic institutes and biotech companies, such as ETH Zurich, MIT, Stanford, Yale, Princeton, Harvard Medical School, Max–Planck–Institute, Fraunhofer–Institute, Moscow Academy of Sciences, London Imperial College and Baxter, Invitrogen, MorphoSys, Roche, and Schering AG.
The result is a testament to the importance of biotechnology in life science, a sure sign that "Modern Biopharmaceuticals" will fuel biotechnologies and help shape the industry of the future.
For pharmaceutists, pharmaceutical chemists, biochemists, molecular biologists, medicinal chemists, as well as those working in the biotechnological and pharmaceutical industries, or biotechnological institutes.
This book is unique in introducing readers to a comprehensive set of recently developed technologies, showing paradigm shifts in the health care system and reflecting these changes in industrial research.
Here, the world′s top scientists and business leaders divulge their first–hand expertise, allowing you to participate in their recent achievements. They all have their own specific contribution and have been carefully selected to provide a multifaceted and unique insight. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel laureates Robert Huber and Thomas R. Cech, as well as authors from the world′s most famous academic institutes and biotech companies, such as ETH Zurich, MIT, Stanford, Yale, Princeton, Harvard Medical School, Max–Planck–Institute, Fraunhofer–Institute, Moscow Academy of Sciences, London Imperial College and Baxter, Invitrogen, MorphoSys, Roche, and Schering AG.
The result is a testament to the importance of biotechnology in life science, a sure sign that "Modern Biopharmaceuticals" will fuel biotechnologies and help shape the industry of the future.
For pharmaceutists, pharmaceutical chemists, biochemists, molecular biologists, medicinal chemists, as well as those working in the biotechnological and pharmaceutical industries, or biotechnological institutes.
Note: Product cover images may vary from those shown
2 of 3
Volume 1
INTRODUCTION
PART I: BIOPHARMACEUTICALS USED IN MOLECULAR MEDICINE
Genes & genomes – correlation between genes, diseases & biopharmaceuticals
siRNA – the magic bullet & other gene therapeutical approaches
Mobilis in mobile – human embryonic stem cells & other sources for cell therapy
Volume 2
PART II: BIOPHARMACEUTICALS AND THEIR MODE OF ACTION
The clotting cascade – lysis, coagulation & a fine–tuned balance
Errare humanum est – what causes cancer & how to selectively fight tumors
Mundus vult decipi – high mutation rates of HIV & new paradigms for treatment
PART III: IMPROVING THE DEVELOPMENT OF BIOPHARMACEUTICALS
Citius, altius, fortius – acceleration by high throughput & ultra–HT
Early target validation – knock–out mice & more
Revolution by evolution – rational design for desire & the scientific art of optimization
Volume 3
PART IV: PRODUCTION OF BIOPHARMACEUTICALS
The industry′s workhorses – mammalian expression systems
A ripe and blooming market – biopharmaceuticals from transgenic animals & plants
Alea non iacta est – improving established expression systems
When success raises its ugly head – outsourcing to uncork the capacity bottleneck
PART V: BIOPHARMACEUTICALS USED FOR DIAGNOSTICS AND IMAGING
From hunter to craftsman – engineering antibodies with nature′s universal toolbox
Find, fight & follow – target–specific troica from Mother Nature′s Pharmacopoiea
Getting insight – sense the urgency for early diagnostics
Volume 4
PART VI: ADVANCED APPLICATION ROUTES FOR BIOPHARMACEUTICALS
Getting inside – quest for the best & how to improve delivery
Pathfinder – new ways for peptides, proteins & Co
Via mala – the stony road of DNA delivery: back–pack, feed–back & pay–back
Getting beyond – rocket science & science fiction
PART VII: FROM TRANSCRIPTION TO PRESCRIPTION
Opening the therapeutic window – between systemic toxicity & lack of efficacy
Happy end – claim to fame & approval
PART VIII: FROM BENCH TO BEDSIDE –
THE AFTERMATHS
Think big & dealmaking for growth – global changes in the health–care sector
News & views – quo vadis, biopharmaceuticals?
Small molecules – light at the end of the tunnel or back to the roots?
INTRODUCTION
PART I: BIOPHARMACEUTICALS USED IN MOLECULAR MEDICINE
Genes & genomes – correlation between genes, diseases & biopharmaceuticals
siRNA – the magic bullet & other gene therapeutical approaches
Mobilis in mobile – human embryonic stem cells & other sources for cell therapy
Volume 2
PART II: BIOPHARMACEUTICALS AND THEIR MODE OF ACTION
The clotting cascade – lysis, coagulation & a fine–tuned balance
Errare humanum est – what causes cancer & how to selectively fight tumors
Mundus vult decipi – high mutation rates of HIV & new paradigms for treatment
PART III: IMPROVING THE DEVELOPMENT OF BIOPHARMACEUTICALS
Citius, altius, fortius – acceleration by high throughput & ultra–HT
Early target validation – knock–out mice & more
Revolution by evolution – rational design for desire & the scientific art of optimization
Volume 3
PART IV: PRODUCTION OF BIOPHARMACEUTICALS
The industry′s workhorses – mammalian expression systems
A ripe and blooming market – biopharmaceuticals from transgenic animals & plants
Alea non iacta est – improving established expression systems
When success raises its ugly head – outsourcing to uncork the capacity bottleneck
PART V: BIOPHARMACEUTICALS USED FOR DIAGNOSTICS AND IMAGING
From hunter to craftsman – engineering antibodies with nature′s universal toolbox
Find, fight & follow – target–specific troica from Mother Nature′s Pharmacopoiea
Getting insight – sense the urgency for early diagnostics
Volume 4
PART VI: ADVANCED APPLICATION ROUTES FOR BIOPHARMACEUTICALS
Getting inside – quest for the best & how to improve delivery
Pathfinder – new ways for peptides, proteins & Co
Via mala – the stony road of DNA delivery: back–pack, feed–back & pay–back
Getting beyond – rocket science & science fiction
PART VII: FROM TRANSCRIPTION TO PRESCRIPTION
Opening the therapeutic window – between systemic toxicity & lack of efficacy
Happy end – claim to fame & approval
PART VIII: FROM BENCH TO BEDSIDE –
THE AFTERMATHS
Think big & dealmaking for growth – global changes in the health–care sector
News & views – quo vadis, biopharmaceuticals?
Small molecules – light at the end of the tunnel or back to the roots?
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
Jörg Knäblein
Note: Product cover images may vary from those shown
